本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SAN FRANCISCO and SUZHOU, China, Sept. 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the Phase 3 clinical trial results for mazdutide, a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with type 2 diabetes (T2D) (DREAMS-2) were presented as a late-breaking oral presentation (Abstract #: LBA 16) at the 60th Annual Meeting of the European Association for the Study of Diabetes® (EASD). The study results demonstrated the superiority of mazdutide to dulaglutide in both glycemic control and body weight reduction in Chinese participants with T2D. Additionally, mazdutide treatment improved several cardiometabolic risk factors, including blood pressure, lipids, serum uric acid and liver enzymes. Detailed results will be published in peer-reviewed journals. Meanwhile, the first Phase 3 study results of mazdutide in the weight loss of overweight/obese subjects (GLORY-1) were reported in oral presentation session of EASD. Mazdutide also works as a breakthrough weight-loss drug that offers dual-targeted fat burning, liver function improvement, and long-lasting weight reduction, providing comprehensive metabolic benefits to support weight loss and promote a healthier life. DREAMS-2 (ClinicalTrials.gov, NCT05606913) enrolled 731 Chinese participants with T2D (mean age 51.8 years, mean baseline HbA1c 8.22%, mean baseline body weight 76.95 kg), whose diabetes was inadequately controlled with metformin alone or in combination with other oral anti-diabetic medications. Participants were randomized to receive mazdutide 4 mg, mazdutide 6 mg or dulaglutide 1.5 mg for 28 weeks. The primary endpoint was the change in HbA1c from baseline to week 28. Superiority of mazdutide to dulaglutide in glycemic control* For the efficacy estimand, after 28 weeks of treatment, mean reductions in HbA1c from baseline were 1.69% and 1.73% for mazdutide 4 mg and mazdutide 6 mg, respectively, demonstrating superiority over dulaglutide 1.5 mg (1.36%). At week 28, 71.2% and 74.2% of participants receiving mazdutide 4 mg and 6 mg, respectively, achieved HbA1c <7.0% compared to 62.1% with dulaglutide. Additionally, 54.8% and 63.1% of participants receiving mazdutide 4 mg and 6 mg, respectively, achieved HbA1c ≤6.5% , compared to 42.1% for dulaglutide. Mazdutide's superiority over dulaglutide in weight loss and HbA1c/weight composite endpoints* After 28 weeks of treatment, participants treated with mazdutide 4 mg and mazdutide 6 mg experienced mean weight reductions of 9.24% and 7.13%, respectively, significantly outperforming dulaglutide (2.86%). At week 28, 62.4% and 78.2% of participants receiving mazdutide 4 mg and mazdutide 6 mg achieved a weight reduction of ≥5%, compared to 26.9% for dulaglutide. Additionally, 50.1% and 64.3% of participants with mazdutide 4 mg and mazdutide 6 mg achieved both a weight reduction of ≥5% and HbA1c < 7.0%, respectively (dulaglutide 19.4%). Improvements on multiple cardiometabolic risk factors by mazdutide Mazdutide treatment also led to significant and clinically meaningful improvements on fasting glucose, post-prandial glucose, waist circumference, blood pressure, lipids, serum uric acid and transaminases, mostly greater than dulaglutide. Detailed results will be published in peer-reviewed journals. Favorable safety and tolerability profile and no new safety signals Mazdutide was well tolerated, with low incidence of TEAEs leading to treatment discontinuation. The overall safety profile was consistent with previous clinical studies of mazdutide, with no new safety signals observed. Gastrointestinal symptoms were the most common adverse events, mostly mild to moderate in severity, transient, and occurring mainly during dose escalation. No severe hypoglycemia was reported with mazdutide, and the incidence of grade 1-2 hypoglycemia was comparable to dulaglutide. Mazdutide is the first GLP-1R/GCGR dual agonist in the regulatory review status, with a first new drug application (NDA) for chronic weight management and a second NDA for T2D currently under review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. Professor Lixin Guo, the principal investigator of the clinical study, Department of Endocrinology in Beijing Hospital, said: "The incidence of type 2 diabetes in China remains high, and a considerable proportion of patients have overweight/obesity, cardiovascular and kidney diseases. In recent years, GLP-1 receptor agonists have offered improved treatment options for patients with type 2 diabetes, providing comprehensive benefits in glucose control, weight management, and cardiovascular and kidney health. As a result, GLP-1-based therapies have become a hot spot and frontier in the development of drugs for metabolic diseases. Mazdutide, one of the fastest-advancing GLP-1R and GCGR dual agonists in clinical development globally, has demonstrated superiority in glucose-lowering and weight-reducing efficacy over dulaglutide in a Phase 3 study of patients with type 2 diabetes. With its additional metabolic benefits and favorable safety profile, mazdutide represents a new generation of GLP-1 therapies for the treatment of type 2 diabetes. I look forward to the clinical availability of mazdutide as soon as possible to provide new treatment options for patients with type 2 diabetes." Dr. Lei Qian, Vice President of Clinical Development of Innovent, said: "China has a large population of people with diabetes, and the task of prevention and treatment is arduous. There is an urgent need for more effective, safer and more convenient innovative drugs. The Phase 3 study results of mazdutide versus dulaglutide reported at EASD were very successful. They showed comprehensive benefits of mazdutide in blood glucose control, weight loss and multiple metabolic indicators. Combined with the results of DREAMS-1, another Phase 3 study of mazdutide as monotherapy in patients with type 2 diabetes, Innovent has submitted an application for the marketing approval of mazdutide for the treatment of type 2 diabetes to the regulatory agency. We look forward to the approval of mazdutide and its potential to benefit a large number of type 2 diabetes patients seeking improvements in glycemic control, weight management and cardiovascular metabolic indicators." About Diabetes According to the 2021 global diabetes overview by the International Diabetes Federation, China leads the world in the number of patients with diabetes, with an estimated 140 million cases in 2021 and projected to reach 174 million by 2045[1]. Poor glycemic control can lead to irreversible microvascular and macrovascular complications, including reduced visual acuity, blindness, renal dysfunction, peripheral neuropathy, myocardial infarction, stroke and amputation[2]. The high prevalence of diabetes and its serious complications pose a significant threat to human health. Currently, various therapeutic approaches are available for diabetes management. In addition to controlling blood glucose, new hypoglycemic drugs are being developed to offer additional benefits such as weight loss, cardiovascular risk reduction and kidney protection[3]. About Mazdutide (IBI362) Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide promotes insulin secretion, lowers blood glucose and reduces body weight similar to GLP-1 receptor agonists. Additionally, it may increase energy expenditure and improve hepatic fat metabolism by activating the glucagon receptor. Mazdutide has strong efficacy in weight loss and lowering glucose levels in clinical studies. It also offers multiple cardio-metabolic benefits, such as reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, while improving insulin sensitivity. Mazdutide has two NDAs accepted by China's NMPA for review, including: For the chronic weight management in adults with obesity or overweight; For the glycemic control in adults with type 2 diabetes. Currently, a total of five Phase 3 studies of mazdutide are underway, including: Phase 3 study conducted in Chinese adults with overweight or obesity (GLORY-1); Phase 3 study conducted in Chinese adults with moderate to severe obesity (GLORY-2); Phase 3 study in newly treated Chinese patients with type 2 diabetes (DREAMS-1); Phase 3 study comparing mazdutide and dulaglutide in Chinese patients with type 2 diabetes (DREAMS-2); Phase 3 study comparing mazdutide and semaglutide in Chinese patients with type 2 diabetes and obesity (DREAMS-3). Among them, GLORY-1, DREAMS-1 and DREAMS-2 have reached the study endpoints. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 11 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn. Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s). Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. References: [1]. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projects for 2045 [published correction appeals in Diabetes Res Clin Pract. 2023 Oct; 204: 110945]. Diabetes Res Clin Pract. 2022; 183: 109119. doi: 10.1016/j.diabres.2021. 109119 [2]. Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. Published online 2016. doi: 10.1016/S2213-8587 (16) 30010-9 [3]. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art. Mol Metab. Published online 2020. doi: 10.1016/j.molmet.2020. 101102* Note: The results of treatment-policy estimand and those of efficacy estimand are consistent.
SANTA CLARA, Calif., Sept. 12, 2024 /PRNewswire/ -- Hillstone Networks, a global leader in cybersecurity solutions, has been recognized in The Forrester Wave™: Microsegmentations Solutions, Q3 2024 report for its advanced microsegmentation offerings, including CloudHive and CloudArmour. The assessment considered 23 criteria to evaluate microsegmentation solution providers. This analysis included identifying, researching, analyzing, and rating the most significant providers in the market. The report offers a detailed comparison of each provider, helping professionals select the most suitable solution for their specific needs. We believe this recognition underscores Hillstone's ability to provide cutting-edge cybersecurity solutions that adapt to complex and dynamic environments. "We are proud to be recognized by Forrester for our offerings in microsegmentation. Our solutions are designed to provide effective protection across a variety of environments, from physical and virtual servers to the cloud," commented Tim Liu, CTO and Co-founder of Hillstone Networks. Hillstone Networks offers advanced microsegmentation solutions through CloudHive and CloudArmour. CloudHive specializes in microsegmentation for virtual environments in private clouds, such as VMware. Its integration with the hypervisor switch allows for effective microsegmentation policy for complete communication within the virtual environment. CloudHive's ability to replace NSX facilitates user transition, while its integrated intrusion detection and prevention system ensures robust and reliable protection. Meanwhile, CloudArmour extends microsegmentation to containers, bare-metal servers, and cloud hosts, providing comprehensive protection across various technological environments. Hillstone Networks offers both solutions under a perpetual license model, a distinctive feature that enhances their flexibility and adaptability in the market. We are in the most advanced era of microsegmentation, where solutions have expanded beyond data centers to include microservices architectures, public clouds, operational technology (OT) environments, and even layer seven. This allows for policies that consider user and process identity. Leading solutions now enable organizations to quickly implement policies without software and leverage technologies like Endpoint Detection and Response (EDR) to enhance security. Emerging technologies like artificial intelligence and automation are transforming cybersecurity. In response to these trends, Hillstone Networks has developed a solution that not only strengthens threat protection but also integrates with other critical technologies such as SD-WAN and Zero Trust Network Access (ZTNA), offering a scalable and future-ready security architecture. About Hillstone Networks Hillstone Networks' integrated cybersecurity approach provides coverage, control, and consolidation to secure the digital transformation of over 28,000 enterprises worldwide. Hillstone Networks is a trusted leader in cybersecurity, protecting critical assets and infrastructure from the edge to the cloud, regardless of where the workload resides. More information is available at www.hillstonenet.com. Media Contact Valeria Duran+1 4085086750inquiry@hillstonenet.com
Study shows priority shifts in Asia's digital native businesses — accelerating tech adoption demands new ways to manage rising complexity and security risks SINGAPORE, Sept. 12, 2024 /PRNewswire/ -- Akamai Technologies, Inc. (NASDAQ: AKAM), the cloud company that powers and protects life online, today revealed in a new study that Asia's digital native businesses (DNBs) face growing security and technology complexity challenges as they accelerate cloud adoption, posing a risk to sustained business growth. In the study, titled Asia's Digital Native Businesses Prioritise Security for Sustainable Growth, DNBs are defined by their aggressive technology adoption. These businesses move at the speed of tech to keep up with customer demands to work, live, and play online. Akamai's study reveals that 9 in 10 DNBs prioritize efficiency and productivity over the next 12 months and are investing in technologies such as cloud computing and application program interface (API)-enabled microservices. According to IDC, DNBs are expected to spend up to $128.9 billion on technology by 2026, with the highest spend growth rate in cloud-based technologies at 37.3%. "Cutting-edge tech is at the core of DNA for digital native businesses — but this is both an opportunity and a challenge. Accelerated tech adoption is the potential Achilles' heel for DNBs, with IT complexity ramping up to expose critical cyber risks that threaten cloud implementations and potentially business performance," said Jay Jenkins, Chief Technology Officer for Akamai Cloud Computing. "For DNBs who are 'born in the cloud' to leverage their full potential, these businesses must find ways to maximize cloud performance and embrace a multicloud approach to avoid vendor lock-in, enhance flexibility, and maximize cloud service usage and costs." Tech-first mindset hampers DNBs' cybersecurity posture DNBs embrace cloud-native design principles and leverage technology as a key differentiator to stay ahead of the competition. With infrastructure built around microservices that operate independently and communicate through APIs, DNBs are able to scale and improve time to market. According to Akamai's new study, 74% of DNBs have either fully migrated to the cloud or are adopting cloud technologies. Respondents in Australia and New Zealand are shifting their perspective on cloud technology from being seen as a disruptive force to becoming an essential business component, with 97% either adopting cloud solutions or exploring cloud adoption. Meanwhile, in India, DNBs are focused on growth and innovation, with the highest AI integration within cloud infrastructure at 98%. Nearly all DNBs in India are either already using cloud solutions or are exploring cloud adoption. Furthermore, as DNBs in India evolve, they are pursuing sustainable growth by emphasizing security, cost optimization, and thorough vendor evaluation. Given their rich history of technological innovation, India's digital natives prioritize vendor performance more than their regional counterparts, ranking second in ASEAN. Asia's DNBs are quick to embrace cloud technologies; this can quickly become a complex matrix of software, systems, and services that exposes DNBs to greater cyber vulnerability. Managing security implications remains a consistent challenge for DNBs, regardless of where they are at in their cloud journey, with 75% of them viewing security as the biggest gap in cloud infrastructure performance and capabilities — above other issues like network latency, data storage, data retrieval, and compute resources. In fact, 44% of respondents stated that the biggest challenge in addressing the security gap stems from rising IT infrastructure complexity. This rush to the cloud has resulted in critical challenges that threaten to derail the pursuit for performance, and DNBs can no longer ignore the increased cyberthreats that come with their pursuit for business growth. Stepping up cloud optimization and API security DNBs are inherently "born in the cloud," but securing life online remains a challenge for them as they struggle to leverage the full potential of emerging technology in cloud, data, and AI. They are prime targets for cyberattacks due to their extensive use of APIs and cloud-based infrastructures, exposing them to greater risk for phishing, account compromise, and ransomware, compared to traditional companies. Akamai's research revealed that DNBs are prioritizing API security at the top of their action list to address cloud security issues, with 9 in 10 stating that API security is a critical or important product feature when evaluating a cloud or security provider. Eighty-seven percent of DNBs state that security features outweigh even performance, reputation, scalability, and cost, when choosing a cloud provider. To combat increasing cyberthreats, DNBs will need support from their technology partners to identify potential weak links that can be exploited by cyber adversaries. "APIs are the connective tissue in modern cloud-native infrastructures. To ensure agile, flexible, and secure operations, a modern security framework must provide advanced API security measures, regular API security audits, and high visibility into API activity," said Jenkins. Sectors most at risk include gaming, high technology, video media, and commerce. In the pursuit of innovation and speed to market, DNBs may launch applications and processes using APIs before security teams can properly evaluate them, resulting in increased exposure to potential cyberthreats. In ASEAN, phishing is a major concern for DNBs, leading them to prioritize investment in anti-phishing technologies more than their counterparts in the APJ region. Phishing tactics have evolved from email-based attacks to now include mobile devices and social media platforms. As a result, ASEAN invests more heavily in anti-phishing technologies compared to its counterparts in the APJ region. As Asia's DNBs tackle these complexity and security challenges on their cloud adoption journey, such insights provide a view into the path ahead for businesses of all backgrounds and cloud maturity. Cloud technologies and API-enabled services are now critical enablers of modern digital business, which will require new tools, skills, and partners to pave the way for successful adoption and implementation. Asia's Digital Native Businesses Prioritise Security for Sustainable Growth was commissioned by Akamai and conducted by Technology Advice. The study surveyed over 200 tech leaders across Australia, New Zealand, Southeast Asia, India, and Greater China to uncover the key business priorities and technology concerns of Asian DNBs. About Akamai Akamai powers and protects life online. Leading companies worldwide choose Akamai to build, deliver, and secure their digital experiences — helping billions of people live, work, and play every day. Akamai Connected Cloud, a massively distributed edge and cloud platform, puts apps and experiences closer to users and keeps threats farther away. Learn more about Akamai's cloud computing, security, and content delivery solutions at akamai.com and akamai.com/blog, or follow Akamai Technologies on X, formerly known as Twitter, and LinkedIn. MEDIA CONTACT: akamai-apjhub@edelman.com
NEW YORK, Sept. 12, 2024 /PRNewswire/ -- Rakuten Advertising, the leading global affiliate marketing network, announced the launch of its AI-driven Partnership Discovery solution for advertisers in the Asia-Pacific (APAC) market. This innovative solution, which has already transformed how advertisers find new partners in the US and UK, will empower advertisers in the Rakuten Advertising APAC network to identify the most effective publisher partners for high-performance affiliate campaigns. In addition to its new availability to advertisers in the APAC region, Partnership Discovery now has new industry-leading search functionality that relies on network performance data to uncover valuable publisher audiences. This functionality provides advertisers with a unique solution for identifying publishers with a proven history of selling a specific brand. "This expansion of Partnership Discovery is part of our ongoing initiative to be a leader in affiliate marketing innovation and harness the power of AI to deliver stronger partnerships with publishers," says Nick Stamos, CEO of Rakuten Advertising. "With our vast database of transactional data, use of advanced machine learning models, and a robust AI-forward infrastructure, Rakuten Advertising is leading the way to help brands unlock efficient affiliate and influencer marketing strategies." Partnership Discovery enables advertisers to: Assign products with an accurate category tag from Google's Product Taxonomy Analyze billions of annual sales delivered through the Rakuten Advertising network to identify the publishers that deliver the best performance in their product category Offer advertisers alternative search terms and categories to find optimal publisher partners to reach audiences at both category and product levels The new brand search functionality builds on the existing AI capabilities of Partnership Discovery and unlocks the capability for advertisers to: Search by brand name to receive recommendations for publishers with a proven history of selling specific brands Identify publishers that reach niche audiences, such as luxury buyers, by searching for high-end brand names, allowing advertisers to tap into specific, high-value consumer segments Partnership Discovery, including the new brand search functionality, is available now to all Rakuten Advertising clients in the APAC, US and UK markets. For more information, visit www.rakutenadvertising.com. About Rakuten Advertising Rakuten Advertising delivers performance-driven, brand-driven, and people-driven ad solutions that help the world's top brands connect with unique, highly engaged audiences – from first impression to final sale. Backed by Affiliate Intelligence, industry-leading technology, global media properties, and the largest, high-quality partner network, Rakuten Advertising taps into data and experience to develop the strategies and ad experiences that will drive engagement, sales, loyalty, and beyond. A leader in the industry since its beginnings, Rakuten Advertising is a division of Rakuten Group, Inc. (4755: TOKYO), one of the world's leading internet service companies. The company is headquartered in San Mateo, California, with offices throughout EMEA, APAC, LATAM, and North America. Learn more at RakutenAdvertising.com. Media Contact: steven.shaw@rakuten.com
MONTREAL and CAMPBELL, Calif., Sept. 12, 2024 /PRNewswire/ -- From ALL IN 2024: WEKA, the AI-native data platform company, and S&P Global Market Intelligence unveiled the findings of their second annual Global Trends in AI report. The global study, conducted by S&P Global Market Intelligence and commissioned by WEKA, surveyed over 1500 AI practitioners and decision-makers to understand the underlying trends influencing AI adoption and implementation. It also provides insights into the key practices of organizations now emerging as leaders in the AI revolution. "One of the most striking takeaways from our 2024 Trends In AI study is the astonishing rate of change that's taken place since the onset of ChatGPT 3 and the first wave of generative AI models reached the market in early 2023. In less than two years, generative AI adoption has eclipsed all other AI applications in the enterprise, defining a new cohort of AI leaders and shaping an emergent market of specialty AI and GPU cloud providers," said John Abbott, principal research analyst at 451 Research, part of S&P Global Market Intelligence. "We can now see a direct correlation forming with those with a higher degree of AI maturity and increased revenue, operating efficiencies, and faster time to market for product innovation."1 Additionally, the new report underscored that, although AI is now more widely implemented in global organizations, obstacles remain in deploying AI successfully at scale. Data architectures were a reoccurring theme in this year's report, defining the first wave of emerging AI leaders while many enterprises still struggle to scale. GPU availability was another commonly cited challenge, and regional disparities persist, suggesting global AI demand is outpacing access to AI accelerators and GPUs needed to power AI projects. Many organizations have successfully embraced AI infrastructure-as-a-service offerings from hyperscale cloud providers and an emergent market of new AI and GPU cloud markets to overcome this supply-demand gap and fuel their generative AI initiatives. Key findings of the 2024 Trends In AI report include: AI Applications Are Increasingly Pervasive In the Enterprise 33% of survey respondents have reached enterprise scale, with AI projects being widely implemented and driving significant business value, up from 28% last year. North America leads in enterprise AI adoption, with 48% of North American respondents indicating that AI is widely implemented, compared to APAC (26%) and EMEA (25%). Product improvement and operational effectiveness are key investment drivers, with organizations leveraging AI to improve product or service quality (42%), target increased revenue growth (39%), improve workforce productivity (40%) and IT efficiencies (41%), and accelerate their overall pace of innovation (39%). Generative AI Has Rapidly Eclipsed Other AI Applications An astonishing 88% of organizations are actively investigating generative AI, far outstripping other AI applications such as prediction models (61%), classification (51%), expert systems (39%) and robotics (30%). Generative AI adoption is exploding: 24% of organizations say they already see generative AI as an integrated capability deployed across their organization. 37% have generative AI in production but not yet scaled. Just 11% are not investing in generative AI at all. Many AI Projects Fail to Scale — Legacy Data Architectures Are the Culprit On average, organizations have 10 AI projects in the pilot phase and 16 in limited deployment, but only six are deployed at scale. Data quality is the top challenge when moving AI projects into production. The most frequently cited technological inhibitors to AI/ML deployments are storage and data management (35%)—significantly greater than computing (26%), security (23%), and networking (15%). This is evidence that weak data foundations impede many organizations' AI projects. GPU Availability Continues To Be Constrained, Shaping Infrastructure Decision-Making Four in 10 organizations suggest access to AI accelerators is a leading consideration in their infrastructure decision-making, and 30% cite GPU availability among their top three most serious challenges in moving AI models into production. Key channels for companies to access GPUs: respondents leverage hyperscale public clouds (46%) and – increasingly – GPU cloud service providers (32%) for model training. Concerns About AI's Environmental Impact Persist But Are Not Slowing Adoption Nearly two-thirds (64%) of organizations say they are concerned about the impact of AI/machine learning (ML) projects on their energy use and carbon footprint; 25% indicate they are very concerned. 42% of organizations indicated that they have invested in energy-efficient IT hardware/systems to address the potential environmental impacts of their AI initiatives over the past 12 months. Of those, 56% believe this has had a "high" or "very high" impact. "Like the internet, the smartphone, and cloud computing before it, AI represents a paradigm shift that will leave an indelible mark on business and society and is already defining a new generation of industry leaders and disruptors," said Liran Zvibel, cofounder and CEO at WEKA. "Unlike past technology transitions, AI's adoption and maturation are growing with unprecedented velocity. The findings of S&P Global's 2024 Trends In AI report underscore that the first wave of AI leaders is already scaling their competitive advantage by accelerating organizational and product innovation with faster time to market, positively impacting their bottom line. Those who are less AI mature are at risk of falling behind. To survive and thrive in the AI era, organizations must find trusted technology partners to help them cross the chasm and ensure they can agilely adapt to whatever the future brings." To read the full 2024 Global Trends in AI study from S&P Global Market Intelligence, visit www.weka.io/trends-in-AI. Research Methodology The findings in S&P Global Market Intelligence's 2024 Global Trends in AI report draw from a survey fielded in Q2 2024 of 1,519 AI/ML decision makers/influencers in enterprises, research organizations, and AI providers building AI technologies, products, and solutions. The study prioritized respondents with AI/ML projects in pilots and production environments across the following industries: aerospace and defense, automotive, energy/oil and gas, finance, government, healthcare, higher education, IT and services, life sciences, manufacturing, media/entertainment, telecommunications, transportation and logistics, and utilities. The report also draws on contextual knowledge of additional research conducted by S&P Global. About WEKA WEKA is architecting a new approach to the enterprise data stack built for the AI era. The WEKA® Data Platform sets the standard for AI infrastructure with a cloud and AI-native architecture that can be deployed anywhere, providing seamless data portability across on-premises, cloud, and edge environments. It transforms legacy data silos into dynamic data pipelines that accelerate GPUs, AI model training and inference, and other performance-intensive workloads, enabling them to work more efficiently, consume less energy, and reduce associated carbon emissions. WEKA helps the world's most innovative enterprises and research organizations overcome complex data challenges to reach discoveries, insights, and outcomes faster and more sustainably – including 12 of the Fortune 50. Visit www.weka.io to learn more, or connect with WEKA on LinkedIn, X, and Facebook. WEKA and the WEKA logo are registered trademarks of WekaIO, Inc. Other trade names used herein may be trademarks of their respective owners. 1 451 Research, part of S&P Global Market Intelligence, Discovery Report "Global Trends in AI," August 2024
BRISBANE, Australia, Sept. 12, 2024 /PRNewswire/ -- White Rook Cyber is excited to announce they have strategically merged with the privately owned Screwloose IT (SL). The merger of White Rook Cyber, a premium industry leader in Cyber Security, Offensive Security (including penetration testing and technical security) and GRC Advisory Services (including compliance auditing and technical security) and Managed Security Services, and SL, a national managed IT services provider who has a strong focus on cyber platforms, allows national expansion and enhanced capabilities for both White Rook Cyber and SL clients. Customers are now able to access a complete premium Managed Cyber (in house) solution with high end reporting (white label available) which is integrated with MS security baselines, within an inhouse 24/7 SOC/SIEM, email protection and phishing protection, high level EDR with advanced browser level security, Systems Patching Controls, structured Security Awareness Program and the introduction of a cost effective GRC service offering all included for a fraction of the cost of other competitors. This strategic merger further allows White Rook clients the ability to have a one stop shop for all their digital needs. In addition to the above, this merger further enables clients easy access to SL's full service offering, which includes but is not limited to: 30+ technicians/incident responders Premium Cisco & Microsoft Partnerships In house Dev team, who specialise in software development and website development Digital marketing – website hosting, SEO, PPC and graphics Telecommunications – NBN, phone lines and WiFi Physical security measures – access control, alarm systems, CCTV cameras, Data Cabling and TV antennas IT Managed Services – including cloud hosting and services ERP/Greentree support And more! General Manger of SL, Alex Niazov, stated "we are excited to welcome White Rook Cyber to the SL family and to mutually expand both companies service capabilities". About White Rook Cyber White Rook Cyber is an Australian company reshaping how clients build digital resilience and cyber security capability through Awareness, Advisory, Leadership and Training. Our focus is on understanding cyber security vulnerabilities and gaps within your environment, across business, people, processes, and technology. At our core, we care about keeping you safe! We look into all possible areas of concern, from easy-to-spot issues to hidden dangers. This includes everything, from information that's accidentally been made public, to the potential loss of important data. We actively take steps to secure every possible entry point, thus minimizing the risk of a cyber attack. About Screwloose IT Screwloose IT works a little differently to most companies. Our service and success is attributed to the simplicity of our systems and processes. No politics, no sales reps, no lock-in contracts. Just high-quality IT solutions. Managed IT Services - We proactively monitor and support every aspect of your business's technology to prevent problems before they arise and resolve them quickly and efficiently. Hosting & Cloud Solutions - Our hosting and private cloud solutions are built for agility, enhanced productivity, and cost reduction. ERP Consulting - We can support you with a range of ERP options to help power better decision making and drive profits and improve your oversite and business workflows. Custom Development - Custom applications and software; unique websites; mobile apps and more. We help you build solutions that meet your business goals. Digital Marketing & SEO - Take the guess work out of lead generation. We create and manage a digital marketing solution that you can rely on to grow your business. Telco Solutions - NBN, Fibre Internet, Fixed Wireless, Hosted PBX, VoIP, and more.
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
